Effect of oral BCG in cutaneous melanoma

Evaluation of oral BCG effect on DFS and OS as an adjuvant treatment for advanced cutaneous melanoma Patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251104067875N1

Enrollment

Registered

2025-11-18

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous melanoma. Malignant melanoma of skin, unspecified

Interventions

The intervention group, who receive oral treatment with 600 mg of Pastozis (BCG) weekly.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced cutaneous melanoma patients (Clark 4 or 5) Life expectancy of at least two years

Exclusion criteria

Exclusion criteria: Early melanoma patients Pregnant or breast-feeding patients Allergy to seton or BCG

Design outcomes

Primary

Measure	Time frame
Disease free survival and overall survival. Timepoint: September 2025 - 2027. Method of measurement: Physical Examination and Pet-Scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansour Nateghi

Shahid Beheshti University of Medical Sciences

mansournateghi@gmail.com+98 919 762 9745

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026